{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:54:29Z","timestamp":1788504869367,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s11739-023-03208-9","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T04:42:18Z","timestamp":1675744938000},"page":"535-547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Direct oral anticoagulants in patients with a left-sided bioprosthetic heart valve: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"18","author":[{"given":"Silvia","family":"Galliazzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Pelitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Campiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Squizzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"key":"3208_CR1","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0140-6736(06)69208-8","volume":"368","author":"VT Nkomo","year":"2006","unstructured":"Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M (2006) Burden of valvular heart diseases: a population-based study. Lancet 368:1005\u20131011. https:\/\/doi.org\/10.1016\/S0140-6736(06)69208-8","journal-title":"Lancet"},{"key":"3208_CR2","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(09)60780-7","volume":"374","author":"JC Sun","year":"2009","unstructured":"Sun JC, Davidson MJ, Lamy A, Eikelboom JW (2009) Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet 374:565\u2013576. https:\/\/doi.org\/10.1016\/S0140-6736(09)60780-7","journal-title":"Lancet"},{"key":"3208_CR3","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/0735-1097(94)00563-6","volume":"25","author":"M Heras","year":"1995","unstructured":"Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR, Danielson GK, Orszulak TA, Pluth JR, Puga FJ, Schaff HV, Larsonkeller JJ (1995) High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 25:1111\u20131119. https:\/\/doi.org\/10.1016\/0735-1097(94)00563-6","journal-title":"J Am Coll Cardiol"},{"key":"3208_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(98)00583-9","author":"WB Kannel","year":"1998","unstructured":"Kannel WB, Wolf PA, Benjamin EJ, Levy D (1998) Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. https:\/\/doi.org\/10.1016\/s0002-9149(98)00583-9","journal-title":"Am J Cardiol"},{"key":"3208_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM (2011) ROCKET AF investigators, rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883\u2013891. https:\/\/doi.org\/10.1056\/NEJMoa1009638","journal-title":"N Engl J Med"},{"key":"3208_CR6","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L (2009) RE-LY steering committee and investigators, dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139\u20131151. https:\/\/doi.org\/10.1056\/NEJMoa0905561","journal-title":"N Engl J Med"},{"key":"3208_CR7","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L (2011) ARISTOTLE committees and investigators, apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981\u2013992. https:\/\/doi.org\/10.1056\/NEJMoa1107039","journal-title":"N Engl J Med"},{"key":"3208_CR8","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM (2013) ENGAGE AF-TIMI 48 Investigators, Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093\u20132104. https:\/\/doi.org\/10.1056\/NEJMoa1310907","journal-title":"N Engl J Med"},{"key":"3208_CR9","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) PRISMA Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. https:\/\/doi.org\/10.1136\/bmj.b2535","journal-title":"BMJ"},{"key":"3208_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2021.01.127","author":"CY Shim","year":"2021","unstructured":"Shim CY, Seo J, Kim YJ, Lee SH, De Caterina R, Lee S, Hong GE (2021) Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: a randomized clinical trial. J Thorac Cardiovasc Surg. https:\/\/doi.org\/10.1016\/j.jtcvs.2021.01.127","journal-title":"J Thorac Cardiovasc Surg"},{"key":"3208_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01204.x","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x","journal-title":"J Thromb Haemost"},{"key":"3208_CR12","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldrige SM, Emberson JR, Hernan MA, Hopewell S, Hrobjartsson A, Junqueira DR, Juni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ doi: https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"3208_CR13","doi-asserted-by":"crossref","unstructured":"Deeks J, Higgins J, et al (2019) Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane","DOI":"10.1002\/9781119536604"},{"key":"3208_CR14","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Li T et al (2019) Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane","DOI":"10.1002\/9781119536604"},{"key":"3208_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40268-016-0124-1","volume":"16","author":"AR Dur\u00e3es","year":"2016","unstructured":"Dur\u00e3es AR, de Souza RP, de Almeida NB, Albuquerque FP, de Bulh\u00f5es FV, de Souza Fernandes AM, Aras R (2016) Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: DAWA pilot study. Drugs R D 16:149\u2013154. https:\/\/doi.org\/10.1007\/s40268-016-0124-1","journal-title":"Drugs R D"},{"issue":"13S","key":"3208_CR16","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1016\/S0735-1097(16)32195-7","volume":"67","author":"G Renda","year":"2016","unstructured":"Renda G, De Caterina R, Carnicelli A, Nordio F, Mercuri M, Ruff C, Giugliano R (2016) Outcomes in 2824 patients with valvular heart disease treated with edoxaban or warfarin in the engage AF-TIMI 48 trial. J Am Coll Cardiol 67(13S):2194","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"3208_CR17","first-page":"2996","volume":"40","author":"JE Strange","year":"2019","unstructured":"Strange JE, Sindet-Pedersen C, Staerk L, Grove EL, Gerds TA, Torp-Pedersen C, Gislason GH, Butt JH, Fosboel EL, Olesen JB (2019) Dabigatran versus vitamin K antagonists in patients with atrial fibrillation and valvular heart disease. Eur Heart J 40(1):2996","journal-title":"Eur Heart J"},{"key":"3208_CR18","doi-asserted-by":"publisher","first-page":"e002776","DOI":"10.1161\/JAHA.115.002776","volume":"5","author":"L Di Biase","year":"2016","unstructured":"Di Biase L (2016) Use of direct oral anticoagulants in patients with atrial fibrillation and valvular heart lesions. J Am Heart Assoc 5:e002776. https:\/\/doi.org\/10.1161\/JAHA.115.002776","journal-title":"J Am Heart Assoc"},{"key":"3208_CR19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00392-015-0919-z","volume":"105","author":"A Yadlapati","year":"2016","unstructured":"Yadlapati A, Groh C, Malaisrie SC, Gajjar M, Krise J, Meyers S, Passman R (2016) Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves. Clin Res Cardiol 105:268\u2013272. https:\/\/doi.org\/10.1007\/s00392-015-0919-z","journal-title":"Clin Res Cardiol"},{"key":"3208_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ijcard.2016.02.005","volume":"209","author":"PA Noseworthy","year":"2016","unstructured":"Noseworthy PA, Yao X, Shah ND, Gersh BJ (2016) Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease. Int J Cardiol 209:181\u2013183. https:\/\/doi.org\/10.1016\/j.ijcard.2016.02.005","journal-title":"Int J Cardiol"},{"key":"3208_CR21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40256-020-00398-x","volume":"20","author":"ML Hampton","year":"2020","unstructured":"Hampton ML, Tellor KB, Armbruster AL, Theodos G, Schwarze MW (2020) Evaluation of the safety and effectiveness of direct-acting oral anticoagulants in patients with atrial fibrillation and coexisting valvular heart disease. Am J Cardiovasc Drugs 20:611\u2013617. https:\/\/doi.org\/10.1007\/s40256-020-00398-x","journal-title":"Am J Cardiovasc Drugs"},{"key":"3208_CR22","doi-asserted-by":"publisher","first-page":"JC43","DOI":"10.7326\/ACPJ202104200-043","volume":"174","author":"YX Gue","year":"2021","unstructured":"Gue YX, Lip GYH (2021) In patients with AF and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin for time to clinical events. Ann Intern Med 174:JC43. https:\/\/doi.org\/10.7326\/ACPJ202104200-043","journal-title":"Ann Intern Med"},{"key":"3208_CR23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1253\/circj.CJ-21-1029","volume":"86","author":"Y Kondo","year":"2022","unstructured":"Kondo Y, Kobayashi Y (2022) Use of novel antithrombotic therapies for patients with atrial fibrillation and bioprosthetic valves. Circ J 86:425\u2013426. https:\/\/doi.org\/10.1253\/circj.CJ-21-1029","journal-title":"Circ J"},{"key":"3208_CR24","doi-asserted-by":"publisher","first-page":"e026666","DOI":"10.1161\/JAHA.122.026666","volume":"11","author":"A Mentias","year":"2022","unstructured":"Mentias A, Saad M, Michael M, Nakhla S, Menon V, Harb S, Chaudhury P, Johnston D, Saliba W, Wazni O, Svensson L, Desai MY, Kapadia S (2022) Direct oral anticoagulants versus warfarin in patients with atrial fibrillation and valve replacement or repair. J Am Heart Assoc 11:e026666. https:\/\/doi.org\/10.1161\/JAHA.122.026666","journal-title":"J Am Heart Assoc"},{"key":"3208_CR25","doi-asserted-by":"publisher","first-page":"e0262580","DOI":"10.1371\/journal.pone.0262580","volume":"17","author":"C Christersson","year":"2022","unstructured":"Christersson C, Held C, Modica A, Westerbergh J, Batra G (2022) Oral anticoagulant treatment after bioprosthetic valvular intervention or valvuloplasty in patients with atrial fibrillation-A SWEDEHEART study. PLoS ONE 17:e0262580. https:\/\/doi.org\/10.1371\/journal.pone.0262580","journal-title":"PLoS ONE"},{"key":"3208_CR26","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa2029603","volume":"383","author":"HP Guimar\u00e3es","year":"2020","unstructured":"Guimar\u00e3es HP, Lopes RD, de Barros E, Silva PGM, Liporace IL, Sampaio RO, Tarasoutchi F, Hoffmann-Filho CR, de Lemos R, Soares Patriota R, Leiria TLL, Lamprea D, Precoma DB, Atik FA, Silveira FS, Farias FR, Barreto DO, Almeida AP, Zilli AC, de Souza Neto JD, Cavalcante MA, Fugueira FAMS, Kojima FCS, Damiani L, Santos RHN, Valeis N, Campos VB, Saraiva JFK, Fonseca FH, Pinto IM, Magalh\u00e3es CC, Ferreira JFM, Alexander JH, Pavanello R, Cavalcanti AB, Berwanger O (2020) Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med 383:2117\u20132126. https:\/\/doi.org\/10.1056\/NEJMoa2029603","journal-title":"N Engl J Med"},{"key":"3208_CR27","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1161\/CIRCULATIONAHA.116.026714","volume":"135","author":"AP Carnicelli","year":"2017","unstructured":"Carnicelli AP, De Caterina R, Halperin JL, Renda G, Ruff CT, Trevisan M, Nordio F, Mercuri MF, Antman E, Giugliano RP (2017) Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves. Circulation 135:1273\u20131275. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.026714","journal-title":"Circulation"},{"key":"3208_CR28","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/clc.23178","volume":"42","author":"PO Guimar\u00e3es","year":"2019","unstructured":"Guimar\u00e3es PO, Pokorney SD, Lopes RD, Wojdyla DM, Gersh BJ, Giczewska A, Carnicelli A, Lewis BS, Hanna M, Wallentin L, Vinereanu D, Alexander JH, Granger CB (2019) Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial. Clin Cardiol 42:568\u2013571. https:\/\/doi.org\/10.1002\/clc.23178","journal-title":"Clin Cardiol"},{"key":"3208_CR29","doi-asserted-by":"publisher","unstructured":"Duan L, Doctor JN, Adams JL, Romley JA, Nguyen LA, An J, Lee MS (2021) Comparison of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and bioprosthetic heart valves. Am J Cardiol. 146: 22\u20138.https:\/\/ doi: https:\/\/doi.org\/10.1016\/j.amjcard.2021.01.016.","DOI":"10.1016\/j.amjcard.2021.01.016"},{"key":"3208_CR30","doi-asserted-by":"publisher","unstructured":"Pasciolla S, Zizza LF, Le T, Wright K (2020) Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin After Bioprosthetic Valve Replacements, Clin DrugInvestig. 40: 839\u201345. https:\/\/ doi: https:\/\/doi.org\/10.1007\/s40261-020-00939-x.","DOI":"10.1007\/s40261-020-00939-x"},{"key":"3208_CR31","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1016\/j.clinthera.2019.10.008","volume":"41","author":"V Russo","year":"2019","unstructured":"Russo V, Carbone A, Attena E, Rago A, Mazzone C, Proietti R, Parisi V, Scotti A, Nigro G, Golino P, D\u2019Onofrio A (2019) Clinical benefit of direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic heart valves. Clin Ther 41:2549\u20132557. https:\/\/doi.org\/10.1016\/j.clinthera.2019.10.008","journal-title":"Clin Ther"},{"key":"3208_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.athoracsur.2021.03.016","volume":"113","author":"VA Mannacio","year":"2022","unstructured":"Mannacio VA, Mannacio L, Antignano A, Mauro C, Mastroroberto P, Musumeci F, Zebele C, Iannelli G (2022) New oral anticoagulants versus warfarin in atrial fibrillation after early postoperative period in patients with bioprosthetic aortic valve. Ann Thorac Surg 113:75\u201382. https:\/\/doi.org\/10.1016\/j.athoracsur.2021.03.016","journal-title":"Ann Thorac Surg"},{"key":"3208_CR33","doi-asserted-by":"publisher","first-page":"355","DOI":"10.5603\/CJ.a2021.0158","volume":"29","author":"M Piepiorka-Broniecka","year":"2022","unstructured":"Piepiorka-Broniecka M, Michalski TA, Figatowski T, Wojtowicz A, Jurowiecki J, Stanska A, Rogowski J, Jaguszewski MJ (2022) NOAC versus warfarin in the treatment of atrial fibrillation during the first three months after bioprosthetic aortic valve replacement. Cardiol J 29:355\u2013357. https:\/\/doi.org\/10.5603\/CJ.a2021.0158","journal-title":"Cardiol J"},{"key":"3208_CR34","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955\u2013962. https:\/\/doi.org\/10.1016\/S0140-6736(13)62343-0","journal-title":"Lancet"},{"key":"3208_CR35","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL (2021) Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European society of cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC. Eur Heart J 42:373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612","journal-title":"Eur Heart J"},{"issue":"7","key":"3208_CR36","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","volume":"43","author":"A Vahanian","year":"2022","unstructured":"Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M, Haugaa KH, Jeppsson A, J\u00fcni P, Pierard L, Prendergast BD, S\u00e1daba JR, Tribouilloy C, Wojakowski W (2022) 2021 ESC\/EACTS guidelines for the management of valvular heart disease. Eur Heart J 43(7):561\u2013632. https:\/\/doi.org\/10.1093\/eurheartj\/ehab395","journal-title":"Eur Heart J"},{"key":"3208_CR37","doi-asserted-by":"publisher","first-page":"00589","DOI":"10.1016\/j.amjmed.2021.08.026","volume":"21","author":"R Cardoso","year":"2021","unstructured":"Cardoso R, Ternes CMP, Justino GB, Fernandes A, Rocha AV, Knijnik L, d\u2019Avila A, Lopes RD (2021) Non-vitamin K antagonists versus warfarin in patients with atrial fibrillation and bioprosthetic valves: a systematic review and meta-analysis. Am J Med 21:00589\u201300591. https:\/\/doi.org\/10.1016\/j.amjmed.2021.08.026","journal-title":"Am J Med"},{"key":"3208_CR38","doi-asserted-by":"publisher","first-page":"e211259","DOI":"10.1001\/jamanetworkopen.2021.1259","volume":"3","author":"A Kalra","year":"2021","unstructured":"Kalra A, Raza S, Jafry BH, King HE, Lahorra JA, Svensson LG, Kapadia SR (2021) Off-label use of direct oral anticoagulants in patients receiving surgical mechanical and bioprosthetic heart valves. JAMA New Open 3:e211259. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.1259","journal-title":"JAMA New Open"},{"key":"3208_CR39","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","volume":"385","author":"NM Van Mieghem","year":"2021","unstructured":"Van Mieghem NM, Unverdorben M, Hengstenberg C, M\u00f6llmann H, Mehran R, L\u00f3pez-Otero D, Nombela-Franco L, Moreno R, Nordbeck P, Thiele H, Lang I, Zamorano JL, Shawl F, Yamamoto M, Watanabe Y, Hayashida K, Hambrecht R, Meincke F, Vranckx P, Jin J, Boersma E, Rod\u00e9s-Cabau J, Ohlmann P, Capranzano P, Kim HS, Pilgrim T, Anderson R, Baber U, Duggal A, Laeis P, Lanz H, Chen C, Valgimigli M, Veltkamp R, Saito S, Dangas GD (2021) Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med 385:2150\u20132160. https:\/\/doi.org\/10.1056\/NEJMoa2111016","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1007\/s11739-023-03257-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000}}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-023-03208-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-023-03208-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-023-03208-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T15:24:02Z","timestamp":1690644242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-023-03208-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["3208"],"URL":"https:\/\/doi.org\/10.1007\/s11739-023-03208-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11739-023-03257-0","asserted-by":"object"}]},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,7]]},"assertion":[{"value":"14 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11739-023-03257-0","URL":"https:\/\/doi.org\/10.1007\/s11739-023-03257-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.G. had honoraria for speaking at symposia from Pfizer and Daiichi-Sankyo and supports for attending meetings from Bayer, Daiichi-Sankyo and Pfizer; V.P. and L.C. had no conflict of interest to disclose; D.P had honoraria for educational events from Pfizer, Daiichi-Sankyo and Boehringer; A.S. had honoraria for lectures and\/or participation on advisory board from Daiichi Sankyo, Bayer, Pfizer, Bristol-Myers Squibb, Sanofi, Werfen, Alexion, Roche, and Viatris.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal right statement and informed consent"}}]}}